Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BCAX Bicara Therapeutics

圣诞节休市 12-24 13:00:00 EST

19.12

+0.37

+1.97%

盘后19.12

+0.000.00%

14:59 EST

最高19.12	最低18.00	成交量22.79万
今开18.67	昨收18.75	日振幅5.97%
总市值10.40亿	流通市值6.02亿	总股本5,442万
成交额426.78万	换手率0.72%	流通股本3,151万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":19.12,"timestamp":1735063200000,"preClose":18.75,"halted":0,"volume":227946,"hourTrading":{"tag":"盘后","latestPrice":19.12,"preClose":19.12,"latestTime":"14:59 EST","volume":1651,"amount":31566.5,"timestamp":1735070375305},"delay":0,"floatShares":31505799,"shares":54415619,"eps":-18.087975,"marketStatus":"圣诞节休市","marketStatusCode":7,"change":0.37,"latestTime":"12-24 13:00:00 EST","open":18.67,"high":19.12,"low":18,"amount":4267772.096418,"amplitude":0.059733,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-18.087975,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1735203600000},"adr":0,"listingDate":1726200000000,"adjPreClose":18.75,"preHourTrading":{"tag":"盘前","latestPrice":18.24,"preClose":18.75,"latestTime":"07:00 EST","volume":234,"amount":4039.42968,"timestamp":1735041606364},"postHourTrading":{"tag":"盘后","latestPrice":19.12,"preClose":19.12,"latestTime":"14:59 EST","volume":1651,"amount":31566.5,"timestamp":1735070375305},"volumeRatio":0.3038946494949879,"impliedVol":0.8175,"impliedVolPercentile":0.475},"requestUrl":"/m/hq/s/BCAX","defaultTab":"news","newsList":[{"id":"2484130309","title":"Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元，同比增加23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484130309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484130309?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010416,"startTime":"0","endTime":"0","summary":"11月19日，Bicara Therapeutics Inc.公布财报，公告显示公司2024财年第三财季净利润为-17.48百万美元，同比增加23.50%；其中营业收入为0.00美元，每股基本收益为-0.32美元。机构评级：截至2024年11月19日，当前有4家机构对Bicara Therapeutics Inc.目标价做出预测，其中目标均价为42.05美元，其中最低目标价为36.00美元，最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BCAX"],"gpt_icon":0},{"id":"2483082300","title":"美国研究综述-AMN 医疗保健服务公司、Chart Industries 公司、家得宝公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2483082300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483082300?lang=zh_cn&edition=full","pubTime":"2024-11-13 19:30","pubTimestamp":1731497406,"startTime":"0","endTime":"0","summary":"    路透11月13日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 AMN 医疗保健服务公司、Chart Industries 公司和家得宝公司。* 908 Devices Inc   ：Leerink Partners将目标价从12美元下调至4美元             * 908 Devices Inc   ：Leerink Partners 将其目标价从 \"跑赢大盘 \"下调至 \"跑输大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2249611893.SGD","BBIO","HD","LU2106854487.HKD","CSX","CCCS","HCSG","CRNX","APA","ALB","ABBV","BCAX","ATLC","ARCH","LU2065731478.USD","DAY","LU0256863902.USD","EWTX","BK4566","BMY","LU0128525689.USD","MASS","AESI","CHRW","COGT","CHH","CAVA","GTLS","BK4567","BLFS","BLTE","LU2133065610.SGD","IRON","AXSM","CLF","CHGG","DCOM","BHVN","COLD","SATS","ACLX","AMN","COTY","AISP","FDX","ALIT","BK4505","DOCS","BK4534","DOX"],"gpt_icon":0},{"id":"2477636551","title":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477636551","media":"路透中文","labels":["shareholding","productRelease","event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477636551?lang=zh_cn&edition=full","pubTime":"2024-10-24 20:08","pubTimestamp":1729771713,"startTime":"0","endTime":"0","summary":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元第 3-5 段补充了生物技术行业的背景，第 6-7 段补充了 Septerna 的主要药物。路透10月24日 - 高盛支持的药物开发商赛普特纳公司周四表示，该公司将在美国进行规模更大的首次公开募股，寻求获得 7.431 亿美元的估值，这表明投资者对这一资本密集型行业的乐观情绪。高盛持有 Septerna 5.4% 的股份，该公司目前的目标是通过出售近 1530 万股每股 18 美元的股票筹集 2.75 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nL4S3M01LN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2237443895.HKD","LU2237443382.USD","BK4533","IE00BFXG1179.USD","BIOA","BK4127","IE0034235188.USD","IE0002270589.USD","BK4504","LU1668664300.SGD","BK4588","BK4550","BK4585","LU2237443465.HKD","MBX","LU2237443978.SGD","LU2237443622.USD","BK4552","BK4007","IE0004091025.USD","UPB","LU0106831901.USD","IE0004086264.USD","IE00B19Z3581.USD","BK4139","LU1791807156.HKD","LU2237438978.USD","LU2237443549.SGD","BCAX"],"gpt_icon":0},{"id":"2474031923","title":"更新版 2-随着医疗保健行业上市热潮的兴起，上游生物和另外两家美国生物技术初创公司纷纷定价 IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2474031923","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474031923?lang=zh_cn&edition=full","pubTime":"2024-10-11 08:01","pubTimestamp":1728604880,"startTime":"0","endTime":"0","summary":"更新版 2-随着医疗保健行业上市热潮的兴起，上游生物和另外两家美国生物技术初创公司纷纷定价 IPO全文改写；第 3-10 段增加了细节和背景介绍。路透10月11日 - 周四，三家美国医疗保健初创企业首次公开募股定价，其中包括Upstream Bio UPB.O，该公司以约8.3亿美元的估值募集了2.55亿美元。Dealogic 的数据显示，9 月份是今年医疗保健行业 IPO 最繁忙的月份。CAMP4 的首次公开募股定价为每股 11 美元，远低于其 14 至 16 美元的目标区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nL4T3LN006:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPG","BCAX","BK4135","BIOA","IPO","BK4139"],"gpt_icon":0},{"id":"2474225168","title":"更新版 2-TPG 支持的 CeriBell 在美国首次公开募股中寻求高达 5.78 亿美元的估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2474225168","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474225168?lang=zh_cn&edition=full","pubTime":"2024-10-09 19:56","pubTimestamp":1728475011,"startTime":"0","endTime":"0","summary":"更新版 2-TPG 支持的 CeriBell 在美国首次公开募股中寻求高达 5.78 亿美元的估值CeriBell 发行 1,060 万股股票，此前为 670 万股首次公开募股价格区间从每股 14-16 美元提高到 16-17 美元部分现有投资者可购买价值高达 4000 万美元的股票在第 6、7 和 9-12 段增加了有关公司和首次公开募股的背景和详细信息。路透10月9日 - 由 TPG 支持的医疗设备制造商 CeriBell 周三表示，该公司将在美国进行规模更大的首次公开募股，目标估值高达 5.783 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241009:nL4T3LL12P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","LU0640476718.USD","BK4585","BK4534","LU0234572021.USD","LU0321505868.SGD","LU1162221912.USD","LU0321505439.SGD","LU1496350171.SGD","LU0128525689.USD","LU0980610538.SGD","BIOA","LU1668664300.SGD","LU1791807156.HKD","LU0130103400.USD","LU0053666078.USD","IE00B7SZLL34.SGD","BK4139","LU1894683348.USD","BK4588","LU1201861249.SGD","BCAX","IE00B19Z3581.USD","LU1074936037.SGD","LU1718418525.SGD","LU2129689514.USD","LU0310800965.SGD","LU1894683264.USD","BK4553","BK4135","LU0868494617.USD","LU0070302665.USD","LU1496350502.SGD","IE00BLSP4452.SGD","LU1280957306.USD","LU0971096721.USD","IE00BZ1G4Q59.USD","LU0256863811.USD","IE00BLSP4239.USD","BK4559","LU1267930227.SGD","LU1201861165.SGD","IE00BFXG1179.USD","BK4207","BK4504","BAC","TPG","IE00BKVL7J92.USD","LU0648000940.SGD","LU0417517546.SGD"],"gpt_icon":0},{"id":"2467702802","title":"BUZZ-TPG 支持的 Bicara Therapeutics 在纳斯达克市场首次亮相即大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2467702802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467702802?lang=zh_cn&edition=full","pubTime":"2024-09-14 02:20","pubTimestamp":1726251654,"startTime":"0","endTime":"0","summary":"    9月13日 - ** 癌症疗法开发商 Bicara Therapeutics   在纳斯达克首次上市时股价大涨 50%，最后上涨 39%，报收于 25.02 美元。*  * 由另类资产管理公司 TPG   支持的 Bicara，通过出售 1750 万股股票筹集了 3.15 亿美元，其定价为市场范围的上限。我们可以从今天上市的另外两家公司 中看到明显的迹象，这两家公司都提高了发行规模--IPOX 研究分析师 Lukas Muehlbauer 说。** 摩根士丹利、TD Cowen、Stifel 和 Cantor Fitzgerald 为承销商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","BK4139","PSQ","BK4007","QLD","SQQQ","NQmain","BCAX","ARTL","TQQQ","LENZ","BK4135","TPG","QID",".IXIC"],"gpt_icon":1},{"id":"2467093437","title":"更新版 1-由 TPG 支持的 Bicara Therapeutics 首次上市即股价大涨 46","url":"https://stock-news.laohu8.com/highlight/detail?id=2467093437","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467093437?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:22","pubTimestamp":1726248149,"startTime":"0","endTime":"0","summary":"     路透9月13日 - 周五，Bicara Therapeutics   首次上市时股价大涨近46%，表明投资者对这家由TPG支持的癌症疗法开发商兴趣浓厚。公司股票开盘价为每股26.25美元，使这家总部位于波士顿的公司市值达到12.9亿美元。 Bicara公司在首次公开募股中以每股18美元的价格出售了1750万股股票，筹集了  3.15亿美元，这是其市场发行价范围的上限，此前Bicara公司曾两次增加。近几个月上市的药物开发商Alumis    和Artiva Biotherapeutics   的股价低于其IPO价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","LENZ","BK4135","BK4139","TPG"],"gpt_icon":0},{"id":"1157360442","title":"异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157360442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157360442?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:16","pubTimestamp":1726247788,"startTime":"0","endTime":"0","summary":"9月13日,由风险投资巨头TPG支持的生物科技公司Bicara Therapeutics Inc在纳斯达克上市首日,股价大涨45.8%,引发投资者热捧。Bicara Therapeutics是一家专注于开发创新癌症疗法的生物科技公司。在本次IPO中,公司共发行了1320万股股票,融资2.25亿美元,超出了原计划规模。数据显示,今年美国的IPO市场复苏迹象明显,其中以医疗健康板块为重点领域。有分析认为,Bicara Therapeutics超额认购的成功上市预示着资金青睐具有前景的生物科技创新项目,为行业发展带来了新的契机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"gpt_icon":0},{"id":"2467170624","title":"由 TPG 支持的 Bicara Therapeutics 首次上市即大涨 45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467170624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467170624?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:14","pubTimestamp":1726247670,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月13日 - Bicara Therapeutics   的股价周五首次上市就上涨了45.8%，表明投资者对这家由TPG支持的癌症疗法开发商兴趣浓厚。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX","BK4135","LENZ","TPG"],"gpt_icon":0},{"id":"2467270506","title":"更新 2-Zenas 生物制药公司首次上市股价上涨近 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2467270506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467270506?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:58","pubTimestamp":1726246693,"startTime":"0","endTime":"0","summary":"     路透9月13日 - 百时美施贵宝支持的Zenas生物制药公司  周五在纳斯达克首次公开发行股票 ，股价上涨近8%，这是2024年美国首次公开发行股票市场 在经历两年低迷后复苏的一个迹象。投资者对医疗支付公司 Waystar   和临床生物制药公司 CG Oncology   等公司反应热烈，截至上次收盘，这两家公司的交易价格均高于其 IPO 价格。Zenas与Bicara Therapeutics   和生物技术公司MBX Biosciences   同时上市，因为IPO活动在经历了夏季的低迷后有所回升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4585","BK4534","LU0321505868.SGD","LU1162221912.USD","LU0321505439.SGD","LU1989772840.SGD","LU0098860793.USD","LU1291159041.SGD","BK4127","BK4167","LU0320765646.SGD","LU1720051017.SGD","BK4007","BK4077","BCAX","LU1074936037.SGD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU1548497426.USD","IE00BJT1NW94.SGD","LU0237698245.USD","LU1093756325.SGD","LU0106831901.USD","LU1261432733.SGD","BK4532","ZBIO","LU0882574055.USD","LU2360032135.SGD","LU0868494617.USD","BMY","LU1571399168.USD","SLE","LU1989771016.USD","LU2357305700.SGD","IE0002141913.USD","LU0225771236.USD","LU0061475181.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4559","WAY","LU2125154935.USD","LU1989772923.USD","CGON","LU2242646821.SGD","IPO","LU2125154778.USD","LU0267386448.USD"],"gpt_icon":0},{"id":"2467689857","title":"TPG 支持的 Bicara Therapeutics 在美国首次公开募股中融资 3.15 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467689857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467689857?lang=zh_cn&edition=full","pubTime":"2024-09-13 09:22","pubTimestamp":1726190557,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月13日 - 由TPG支持的癌症疗法开发商Bicara Therapeutics   周四表示，它在美国的首次公开募股中筹集了3.15亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","LENZ","BCAX","BK4139","TPG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bicara.com","stockEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":0.0569},{"period":"3month","weight":-0.273},{"period":"6month","weight":0.0622},{"period":"ytd","weight":0.0622}],"compareEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.1005},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.2651}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司，致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体，它结合了两个临床验证的靶点，即表皮生长因子受体（EGFR）导向的单克隆抗体和结合人类转化生长因子β（TGF-b）的结构域。通过这种双靶向机制，阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖，以及肿瘤微环境（TME）中的免疫抑制性TGF-b信号传导，发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合，将TGF-b抑制剂直接引入TME，他们认为这将导致持久的反应和总生存率或OS的增加，同时减少通常与全身TGF-b抑制相关的不良反应。","exchange":"NASDAQ","name":"Bicara Therapeutics","nameEN":"Bicara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bicara Therapeutics,BCAX,Bicara Therapeutics股票,Bicara Therapeutics股票老虎,Bicara Therapeutics股票老虎国际,Bicara Therapeutics行情,Bicara Therapeutics股票行情,Bicara Therapeutics股价,Bicara Therapeutics股市,Bicara Therapeutics股票价格,Bicara Therapeutics股票交易,Bicara Therapeutics股票购买,Bicara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}